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S U M M A R Y
Objective: To explore the relation between serum sphingolipids and hepatic injury in chronic HBV
infection.
Methods: A cohort of participants including 48 healthy persons, 103 chronic HBV-infected patients
containing chronic hepatitis B (CHB) and HBV-related cirrhosis were included. High performance liquid
chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) was performed to detect serum
sphingolipids. The serological indicators were detected and quantiﬁed. The valid liver biopsy specimens
were acquired from twenty ﬁve CHB.
Results: Twenty four serum sphingolipids were detected. There were eighteen sphingolipids showing
signiﬁcant differences between the healthy control and chronic HBV infection groups. In patients with
chronic HBV infection, fourteen sphingolipids differed signiﬁcantly between CHB and HBV-related
cirrhosis. Among sphingolipids with a signiﬁcant difference in both HBV infection vs healthy control and
CHB vs cirrhosis, seven sphingolipids were independently related to the presence of cirrhosis. SM(d18:1/
24:0), a sphingomyelin (SM) compound, was found to have a negative correlation with model for end-
stage liver disease (MELD) score. Additionally, SM(d18:1/24:0) was demonstrated to have a correlation
with inﬂammation grades by liver biopsy in CHB patients.
Conclusions: Serum sphingolipids have close relation with hepatic injury in chronic HBV infection,
especially that SM(d18:1/24:0) might be a potential serum biomarker.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Chronic liver disease caused by persistent hepatitis B virus
(HBV) infection is a potentially life-threatening disease affecting
the world population. Chronic hepatitis B (CHB) is thought to be
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).the 14th most common cause of death worldwide.1,2 Chronic HBV
infection is characterized by a functionally inefﬁcient immune
system that fails to eliminate HBV from the liver but maintains
continuous hepatocellular injury thought to be responsible for
disease progression.3 Meanwhile, hepatic ﬁbrosis which can occur
at the advanced stage of CHB is primarily driven by the
development of necroinﬂammation in response to hepatic injury.4
It has been suggested that the termination of chronic HBV infection
by available antiviral therapies has been associated with reduced
occurrence of cirrhosis.5 Thus, the prevention of hepatic injury will
beneﬁt for the outcome of CHB.
Sphingolipids constitute structural components of biological
membranes, and regulate the signal processes including prolifera-
tion, differentiation and apoptosis.6 It has been proved that
sphingolipids are enriched in lipid rafts that provide distribution
platform for signal molecules.7–9 And pathogens are able to exploit
lipid rafts to get into their target host cells.10 The in vivo animalciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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repression of host sphingolipid biosynthesis.11 Additionally, the
clinical trial demonstrated that glycosphingolipid alpha-galacto-
sylceramide could be used as a monotherapy for CHB by the
regulation of antiviral immune responses.12 We previously found
that glycosphingolipid and sphingomyelin were closely related to
hepatic necroinﬂammation and steatosis in chronic hepatitis C
patients, respectively.13,14 Recently we also found that serum
dihydroceramide may be a useful prognostic indicator for the early
prediction of HBV-related acute-on-chronic liver failure.15 Accord-
ing to the previous ﬁnding, we speculated that the one or subclass
of sphingolipids might play different roles in different etiologies
and progressing stage of liver disease, and certain sphingolipids
might be involved in the hepatic injury caused by chronic HBV
infection.
Thus, in order to explore the role of sphingolipids in chronic
HBV infection, we included a cohort of patients containing CHB and
HBV-related cirrhosis. With the help of the metabolomics
technologies and available liver biopsy, we analyzed the proﬁle
of serum sphingolipids and the relationship between sphingolipids
and hepatic injury in chronic HBV infection.
2. Materials and methods
2.1. Patients
A cohort of 151 participants including 48 healthy controls,
103 chronic HBV infection patients from Beijing YouAn Hospital
(Capital Medical University, Beijing, China) were included from
2009 to 2013 in the present study. The chronic HBV infection
patients included 52 CHB and 51 HBV-related cirrhosis. Chronic
HBV infection and cirrhosis diagnosis were made in accordance
with established criteria.16 Chronic HBV infection was established
by the positive for HBsAg or HBV DNA using polymerase chain
reaction assays for more than 6 months before enrollment. Patients
with serum bilirubin  10 mg/dl and prothrombin activity (PTA)
<40% were excluded. Additionally, patients with presence of other
causes of liver disease or hepatocellular carcinoma were also
excluded. All healthy controls were negative for HBsAg and
showed normal liver function.
Each subject signed the informed consent at the beginning of
the study. The study protocol was conducted in accordance with
the provisions of the Declaration of Helsinki and approved by the
Institutional Review Board of Beijing YouAn Hospital, Capital
Medical University (Beijing, China).
2.2. HPLC-MS/MS
Fasted blood samples were prospectively collected in
16  100 mm  10 mL BD Vacutainer1 glass serum tubes (Becton
Dickinson, Franklin Lakes, NJ) in the morning of the second day
after the subjects were admitted to the hospital. The tubes were
incubated at room temperature for 20 min to allow the blood to
clot, and then centrifuged at 750  g for 15 min to obtain the
serum. Serum samples were stored at -80 8C immediately after
collection.
The high performance liquid chromatography coupled with
tandem mass spectrometry (HPLC-MS/MS) was performed using
an Agilent 6410B Triple Quad mass spectrometer (Agilent
Technologies Inc., Santa Clara, CA) comprising a triple quadrupole
MS analyzer equipped with an electrospray ionization interface
and an Agilent 1200 RRLC system (HPLC-MS/MS). The HPLC-MS/
MS methodology used in this study was described in our previous
report.15 Sphingolipidomic assays were performed at the Institute
of Materia Medica, Peking Union Medical College (Beijing, China).2.3. Liver Biopsy
Liver biopsies were obtained from CHB patients under
ultrasound guidance. Finally, the valid liver biopsy specimens
were acquired from twenty ﬁve CHB patients. Specimens were
ﬁxed in formalin and embedded in parafﬁn. Specimens longer than
1.5 cm, containing at least six complete portal areas, were
reviewed by two senior pathologists who were unaware of the
patients’ clinical data. The Scheuer scoring system was used to
assess hepatic inﬂammatory activity.17
2.4. Statistical analysis
Data were expressed as mean  standard deviation (SD). In
univariate analysis, depending on the data distribution, differential
signiﬁcance of continuous variables between the two groups was
analyzed by the independent-samples t test or Mann–Whitney
test. Moving forward, the (LR) multivariate logistic regression
analysis was performed, and the P values of entry and removal
were respectively set to 0.05 and 0.1. The diagnostic value of the
indicator was evaluated by the area under the receiver operating
characteristic (ROC) curve analysis. Categorical variables were
analyzed by Pearson x2 test. Correlation analysis was performed by
Spearman’s rank correlation or Pearson correlation. Statistical
analysis was performed using SPSS version 19.0 (Chicago, IL, USA),
while a two-sided P value <0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Characteristics of the participants
The clinical characteristics of participants are summarized in
Table 1. The patients with chronic HBV infection with a mean age of
44.94 years, showed elevated alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) levels. The mean serum HBV
DNA load of these patients was high (3.0E+07 cps/mL). Between
the CHB and cirrhosis groups, the sex proportion resulted in no
signiﬁcant difference between the two patient groups (P = 0.083),
and ALT, total bilirubin (TBIL), albumin, and HBV DNA load showed
statistical differences (P < 0.05). The available liver biopsies were
acquired from twenty ﬁve CHB patients. Inﬂammation grade
1 and 2 were found in most of these patients (80.0%, 20/25). For
HBV-related cirrhosis, the proportion of compensated cirrhosis
accounted for 21.6% (11/51).
3.2. The alteration of serum sphingolipids’ level
Based on our quantitative lipidomic platform, twenty four
serum sphingolipids were detected by HPLC-MS/MS. In order
to explore the role of sphingolipids in chronic HBV infection,
we analyzed the alteration of sphingolipids between healthy
and chronic HBV infection. There were eighteen sphingolipids
which showed signiﬁcant differences (Fig. 1). With the
progress of chronic HBV infection, fourteen sphingolipids
differed signiﬁcantly between CHB and HBV-related cirrhosis
(Fig. 2).
After comparing these sphingolipids, 13 sphingolipids which
differed between healthy and chronic HBV infection, also
presented with signiﬁcant differences between CHB and HBV-
related cirrhosis. Fig. 3 depicts these 13 species in the metabolic
pathway of sphingolipids. Of these sphingolipids, there were
6 ceramides (Cer), 2 hexosylceramide (HexCer), 3 sphingomyelins
(SM), one ceramide-1-phosphate and one dihydroceramide
(dhCer).
Table 1
Clinical characteristics of subjects
Indicator Healthy
(n=48)
Chronic HBV infection P-valuea
Total (n=103) CHB (n=52) HBV-related cirrhosis (n=51)
Age (yr): 37.56  9.89 44.94  13.60 37.44  12.54 52.29  10.21 0.000
Male sex: n (%) 27 (56.3) 84 (81.6) 39 (75.0) 45 (88.2) 0.083
ALT (U/L): 15.62  6.35 135.37  262.18 198.69  331.23 72.05  144.78 0.001
AST (U/L): 20.49  3.72 98.69  161.27 118.23  184.95 79.91  133.88 0.372
TBIL (mmol/L): 12.03  3.77 39.94  46.08 23.67  17.49 55.58  58.32 0.000
Albumin (g/L) - 36.51  6.60 40.89  4.70 32.30  5.31 0.000
Creatinine (mmol/L): - 77.86  78.04 69.39  15.81 85.99  108.07 0.793
PTA (%): - 38.20  40.65 96.09  16.87 64.57  16.25 0.000
HBV DNA (cps/mL) - 3.0E+07  1.1E+08 5.3E+07  1.4E+08 6.5E+05  1.9E+06 0.000
MELD score - - - 10.43  5.78 -
Compensated cirrhosis, n (%) - - - 11(21.6%) -
Inﬂammation gradeb, n(%)
G1 - - 9(36.0%) - -
G2 - - 11(44.0%) - -
G3 - - 5(20.0%) - -
G4 - - 0(0.0%) - -
a P-values are acquired by comparing CHB with HBV-related cirrhosis.
b The available liver biopsies were acquired from 25 CHB patients.
Abbreviations: CHB chronic hepatitis B; ALT alanine aminotransferase; AST aspartate aminotransferase; TBIL total bilirubin; PTA prothrombin activity.
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In order to indentify the sphingolipids which were closely
involved in the presence of cirrhosis, the above 13 sphingolipids
with signiﬁcant difference in both HBV infection and cirrhosis
were analyzed by multivariate analysis according to their species.
The routine indicator age, sex, HBV DNA, ALT, TBIL were also
included. After adjusting for these factors, Cer(d18:1/16:0)-1-P,Figure 1. Serum sphingolipid proﬁle between the healthy control and chronic HBV
a Compared with the healthy group, P-value was less than 0.05. HBV, hepatitis B virus; CerCer(d18:1/24:1), Cer(d18:1/24:0), HexCer(d18:1/16:0), Hex-
Cer(d18:1/18:0), SM(d18:1/18:1), and SM(d18:1/24:0) were
independently related to the presence of cirrhosis (Table 2).
The potential diagnostic capacity of these seven sphingolipids for
distinguishing cirrhosis was also further evaluated by ROC
analysis (Table 3). The AUCs of four sphingolipids reached or
exceeded 0.7. SM(d18:1/18:1) and SM(d18:1/24:0), with AUCs of
more than 0.8 for distinguishing cirrhosis, showed the speciﬁcity
of 0.87 and 0.90, respectively. infection groups
, ceramides; HexCer, hexosylceramide; SM, sphingomyelin; dhCer, dihydroceramide
Figure 2. Serum sphingolipid proﬁle between chronic hepatitis B and HBV-related cirrhosis groups
a Compared with the chronic hepatitis B group, P-value was less than 0.05. CHB, chronic hepatitis B; HBV, hepatitis B virus; Cer, ceramides; HexCer, hexosylceramide; SM,
sphingomyelin; dhCer, dihydroceramide
Figure 3. The sphingolipids with a signiﬁcant difference in both healthy vs chronic HBV infection and CHB vs HBV-related cirrhosis groups
The compounds listed in the boxes were detected and quantiﬁed in this study. Cer, ceramides; HexCer, hexosylceramide; SM, sphingomyelin; dhCer, dihydroceramide
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Table 2
Multivariate analyses according to sphingolipid species
Indicators Odds ratio
(95% CI)
P-value
Ceramide-1-P
Age 1.18 (1.07-1.30) 0.001
ALT 0.99 (0.98-1.00) 0.006
TBIL 1.12 (1.04-1.21) 0.002
Cer(d18:1/16:0)-1-P 0.85 (0.74-0.97) 0.016
Ceramide
Age 1.12 (1.02-1.23) 0.014
Cer(d18:1/18:0) 0.74 (0.53-1.02) 0.068
Cer(d18:1/24:1) 1.03 (1.00-1.06) 0.028
Cer(d18:1/24:0) 0.99 (0.98-1.00) 0.004
Dihydroceramide
Age 1.15 (1.07-1.24) 0.000
ALT 0.99 (0.98-1.00) 0.005
TBIL 1.09 (1.03-1.15) 0.003
Hexosylceramide
Age 1.21 (1.10-1.32) 0.000
TBIL 1.09 (1.04-1.14) 0.000
HexCer(d18:1/16:0) 0.99 (0.99-1.00) 0.001
HexCer(d18:1/18:0) 1.39 (1.02-1.91) 0.039
Sphingomyelin
Age 1.11 (1.02-1.20) 0.011
SM(d18:1/18:1) 0.98 (0.96-0.99) 0.000
SM(d18:1/18:0) 1.01 (1.00-1.01) 0.050
SM(d18:1/24:0) 1.00 (0.99-1.00) 0.018
Abbreviations: CI, conﬁdence interval; ALT, alanine aminotransferase; TBIL, total
bilirubin.
Table 3
ROC analysis of targeted sphingolipids related to identiﬁcation of cirrhosis in
chronic HBV infection
Indicators AUC
(95% CI)
P-value Sensitivity Speciﬁcity
Cer(d18:1/24:1) 0.70 (0.60-0.81) 0.000 0.55 0.87
HexCer(d18:1/18:0) 0.62 (0.51-0.73) 0.041 0.41 0.83
Cer(d18:1/16:0)-1-P 0.65 (0.54-0.75) 0.011 0.86 0.42
Cer(d18:1/24:0) 0.79 (0.69-0.88) 0.000 0.73 0.77
HexCer(d18:1/16:0) 0.65 (0.55-0.76) 0.007 0.73 0.52
SM(d18:1/18:1) 0.91 (0.85-0.97) 0.000 0.90 0.87
SM(d18:1/24:0) 0.82 (0.74-0.91) 0.000 0.67 0.90
Abbreviations: AUC, area under the curve; CI, conﬁdence interval; Cer, ceramides;
HexCer, hexosylceramide; SM, sphingomyelin.
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cirrhosis
MELD score is commonly used clinical indicators to reﬂect the
severity of liver injury in cirrhosis; therefore we analyzed the
correlation between MELD score with sphingolipids. Of sevenFigure 4. Correlation with MELD score in HBV-related cirrhosis
Cer, ceramides; HexCer, hexosylceramide; SM, sphingomyelinsphingolipids independently related to the presence of cirrhosis,
Cer(d18:1/24:0) and SM(d18:1/24:0) were found to have negative
correlation with MELD score. (Fig. 4)
3.5. Correlation of sphingolipids with the inﬂammation grade
according to liver biopsy in CHB
In order to further verify the relationship between Cer(d18:1/
24:0) or SM(d18:1/24:0) which correlated with MELD score and
intrahepatic injury, we also performed liver biopsies in some of the
CHB patients. According to the valid results from biopsies, only
SM(d18:1/24:0) showed a negative correlation with inﬂammation
grades (r=-0.439, P= 0.028). (Fig. 5)
4. Discussion
In the present study, we revealed that on the basis of our
quantitative lipidomic platform, the serum sphingolipids proﬁle
changed in the different progressing stages of chronic HBV
infection. The principal ﬁnding of the study was that it was the
ﬁrst to demonstrate the close relationship between serum
sphingolipids and hepatic injury in chronic HBV infection, which
was validated by liver biopsy in CHB. Meanwhile, the limited
number of the sample size must be acknowledged. However, based
on our results, we clearly demonstrated that serum SM(d18:1/
24:0) which had close relation with both MELD score and
inﬂammation grades might have potential to be involved in
hepatic injury in chronic HBV infection.
Previously we successively found that a certain glycosphingo-
lipid was closely related to hepatic necroinﬂammation in chronic
hepatitis C13 and dihydroceramide was a useful prognostic
indicator for the early prediction of HBV-related acute-on-chronic
liver failure.15 It is interesting to ﬁnd the different kinds of
sphingolipids in our previous ﬁndings related to the different
causes and disease status. Additionally, it is conﬁrmed that
pathogens need to exploit lipid rafts, which sphingolipids are rich
in, to get into the host cells7,10 and proﬁcient virus replication is
crucially supported by lipid biosynthesis.18 Combined with our
previous ﬁndings, we speculated that sphingolipids might play
roles in chronic HBV infection. Therefore, in the present study,
we included a cohort of chronic HBV infection patients who were
without the characteristics of acute-on-chronic liver failure. The
relationship between sphingolipids and hepatic injury in chronic
HBV infection was intensively focused on after the elimination of
inﬂuence of acute-on-chronic liver failure, which is an extreme
severe form of chronic HBV infection, characterized by systemic
inﬂammation response.19 The included patients in the present
study reﬂect the real status due to liver injury. According to the
Figure 5. Correlation with hepatic inﬂammation according to liver biopsy
The middle horizontal line represent the average value, the upper and lower error
bars represent the standard deviation. Cer, ceramides; SM, sphingomyelin
S.-J. Zheng et al. / International Journal of Infectious Diseases 33 (2015) 149–155154results of twenty four serum sphingolipids which were detected by
our quantitative lipidomic platform, eighteen sphingolipids
showed signiﬁcant differences between the healthy control and
HBV-infected persons. Thus, we speculated HBV infection to some
degree might be the reason for the altered metabolism of
sphingolipids. Although the detailed mechanism of how serum
sphingolipids participated during the HBV infection process still
remains mysterious, it suggested that changes of sphingolipids in
peripheral blood were different according to different viral
infection and disease status in the liver.
Our major focus was to ﬁnd the relation between serum
sphingolipids and hepatic injury in chronic HBV infection.
Cirrhosis, which is the most advanced stage of ﬁbrosis represents
a wound-healing response to severe hepatic injury.4 For the
presence or absence of patients with HBV-related cirrhosis, in
multivariate analysis, seven sphingolipids were ﬁnally indentiﬁed
to be all closely related to the presence of cirrhosis after adjusting
for other indicators. Regarding sphingolipid metabolism, the
compounds of sphingolipids which are from ceramides, hexosyl-
ceramide, sphingomyelins, and ceramide-1-phosphate, are all
closed to ceramides in the metabolic pathways. The ROC and
correlation analysis were further performed in these seven
sphingolipids independently related to cirrhosis. We found that
Cer(d18:1/24:0) and SM(d18:1/24:0) were demonstrated to have
correlations with the MELD score, which is usually performed for
evaluating the hepatic injury of patients with cirrhosis and ranking
patients for mortality.20 Besides that, the differential ability
analysis showed SM(d18:1/24:0), with an AUC of more than 0.8,
might have potential for clinically distinguishing advanced hepatic
injury. These results mean that Cer(d18:1/24:0) and SM(d18:1/
24:0) might have the ability to reﬂect indirectly the hepatic injury
in HBV-related cirrhosis, especially for SM(d18:1/24:0).
Liver biopsy is a gold criterion and the most speciﬁc test to
judge hepatic injury.21 However, because of the indications for
biopsy, patients’ willingness, and potential complications, liver
biopsy specimens are very difﬁcult to obtain clinically. In the
present study, we also veriﬁed these sphingolipids by valid liver
biopsies performed in CHB patients. The results showed SM(d18:1/
24:0) which correlated with MELD score, had a negative
correlation with inﬂammation grades. SM(d18:1/24:0) is a
compound of sphingomyelins which is cleaved by one of several
sphingomyelinases (SMases), releasing phosphocholine and cer-
amide.6 Nowadays, although there is no literature to report the
relationship between sphingomyelin and HBV-related liver injury,
sphingomyelinase has been found to play roles in hepatic injury
caused by different causes. In the mouse model, acid sphingo-
myelinase is critical for alcohol-induced liver injury22 and hepatic
ischemia/reperfusion injury.23 Thus, based on our analysis, wespeculated sphingomyelinase, which regulated the metabolism of
sphingomyelin might play a role in HBV-related hepatic injury, and
the metabolite SM(d18:1/24:0) was closely associated with
hepatic injury in chronic HBV infection. However, further studies
are needed for making detailed mechanisms clear in the future.
In summary, based on liver biopsy and metabolomics technol-
ogies, this study was the ﬁrst to ﬁnd that serum sphingolipids,
especially SM(d18:1/24:0) had a close relation to HBV-related liver
injury. Although further study is needed to clarify the detailed
mechanisms in the future, our study provides novel insights into
the molecular mechanism of hepatic injury in chronic HBV
infection.
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